載入中
NASDAQHealthcareMedical - Instruments & Supplies
最新資料
US$53.81
+US$3.83 · +7.66%
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.
前收盤價
US$53.81
+US$3.83 · +7.66%
盤後
US$53.98
+US$0.17 · +0.32%
10月9日 下午7:48 ET
盤中時間採用ET。市場資料可能有所延遲。
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.
日內區間
目前US$53.81
52週區間
目前US$53.81
盤中時間採用ET。市場資料可能有所延遲。
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.
日內區間
目前US$53.81
52週區間
目前US$53.81
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 35萬 USD | — | — | 70萬 USD | 141.8萬 USD |
| 銷貨成本 | 161萬 USD | — | 120.7萬 USD | 1194.4萬 USD | 196.8萬 USD |
| 毛利 | −126萬 USD | — | −120.7萬 USD | −1124.4萬 USD | −55萬 USD |
| 研究與開發 | 4472.1萬 USD | 3233.6萬 USD | 2779.7萬 USD | 2083.9萬 USD | 2864萬 USD |
| 銷售、一般及管理費用 | 3202.9萬 USD | 2392.1萬 USD | 1577.7萬 USD | 2597.4萬 USD | 3382.4萬 USD |
| 營業費用 | 7567.9萬 USD | 5625.7萬 USD | 4236.7萬 USD | 4681.3萬 USD | 6246.4萬 USD |
| 利息收入 | 421萬 USD | 267.2萬 USD | 246.4萬 USD | — | — |
| 利息支出 | — | — | 110萬 USD | 44.8萬 USD | 64.6萬 USD |
| 折舊和攤銷 | 107.1萬 USD | 117.8萬 USD | 120.7萬 USD | 135.5萬 USD | 114.6萬 USD |
| 營業利益 | −7693.9萬 USD | −5625.7萬 USD | −4357.4萬 USD | −5805.7萬 USD | −6301.4萬 USD |
| 淨利 | −7278.1萬 USD | −5358.5萬 USD | −4221萬 USD | −5850.5萬 USD | −6366萬 USD |
公司資料更新於 2026年10月10日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI2791.36萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM2488.14萬0.03%782.66億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF1087.54萬0.01%954億 USD0.05%US$235+0.80%
iShares Russell 2000 Growth ETFIWO867.63萬0.06%139.72億 USD0.24%US$356.78+0.94%
Vanguard Russell 2000 ETFVTWO536.95萬0.03%180億 USD0.06%US$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA531.14萬0.02%217.28億 USD0.03%US$32.79+0.40%
iShares U.S. Medical Devices ETFIHI493.77萬0.14%35.46億 USD0.37%US$51.74+1.25%
Invesco Dorsey Wright Healthcare Momentum ETFPTH307.69萬1.10%2.79億 USD0.74%US$58.757+2.42%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAiShares U.S. Medical Devices ETFIHIInvesco Dorsey Wright Healthcare Momentum ETFPTHAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
